Although they are defined as AML-MRC because of MDS-related cytogenetics, CK-AML should be considered separately because of the presence of a specific mutational profile consisting in a high frequency of TP53 mutations and the absence of other mutations. Here, TP53 is linked to acute myeloid leukemia.